Dose reduction of ibrutinib in chronic lymphocytic leukemia: long-term outcomes from a real-world single-center experience
Mediterranean Journal of Hematology and Infectious Diseases · 31.10.2026 · 18 (1) · e2026090
DOI: 10.4084/mjhid.2026.090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Mediterranean Journal of Hematology and Infectious Diseases, online erschienen am 31.10.2026. Verfasst von Roberta Laureana. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
A real-world experience on dose reduction of ibrutinib in chronic lymphocytic leukemia is reported.
Zitieren
APA
Laureana, R. (2026). Dose reduction of ibrutinib in chronic lymphocytic leukemia: long-term outcomes from a real-world single-center experience. Mediterranean Journal of Hematology and Infectious Diseases, 18(1), e2026090. https://doi.org/10.4084/mjhid.2026.090
Vancouver
Laureana R. Dose reduction of ibrutinib in chronic lymphocytic leukemia: long-term outcomes from a real-world single-center experience. Mediterranean Journal of Hematology and Infectious Diseases. 2026;18(1):e2026090. doi:10.4084/mjhid.2026.090
BibTeX
@article{Laureana2026,
author = {Laureana, Roberta},
title = {Dose reduction of ibrutinib in chronic lymphocytic leukemia: long-term outcomes from a real-world single-center experience},
journal = {Mediterranean Journal of Hematology and Infectious Diseases},
year = {2026},
volume = {18},
number = {1},
pages = {e2026090},
doi = {10.4084/mjhid.2026.090}
}
EUVIMED